# Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)

> **NCT00634309** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 597 (estimated)

## Conditions studied

- Congestive Heart Failure

## Interventions

- **DRUG:** Candesartan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00634309
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-06
- **Primary completion:** 2003-05
- **Final completion:** 2003-05
- **Target enrollment:** 597 (ESTIMATED)
- **Last updated:** 2011-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00634309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00634309, "Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00634309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*